Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)

April 2021

Risks with tofacitinib (Xeljanz, Xeljanz XR) are stacking up.

Xeljanz already has a boxed warning about serious infections...malignancy...thrombosis...and mortality.

Now FDA is alerting about more evidence that Xeljanz is associated with cancer (lung, etc)...and CV events (MI, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote